• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, May 14, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

RUDN scientists synthesized analogues of substances actively used in…

Bioengineer.org by Bioengineer.org
January 26, 2018
in Headlines, Health, Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Tatiana Borisova

RUDN University chemists synthesized new isoquinoline derivatives. Due to their biological activity, these compounds may be applicable in new drugs, from antispasmodics to bactericidal agents. In addition, in the future they may show effectiveness in the treatment of Alzheimer's disease. The scientists presented the results of their experiments in Mendeleev Communications.

"Our study belongs to a fundamental science in which the study of a new reaction and a new reagent, even without an immediate "release" to industry, is an important task itself. However, the substances we worked with, isoquinolines, are actively used in pharmaceuticals (including widely known drotaverine and papaverine)", co-author of the article, Associate Professor, Department of Organic Chemistry, RUDN University Tatyana Borisova reported.

RUDN University chemists synthesized new isoquinoline derivatives, which potentially can have a wide spectrum of biological activity, from bactericidal to antileukemic, from cytotoxicity to antispasmodic properties. In their latest work, they studied the reaction of isoquinolines with dehydrobenzene. The novelty of the study lies precisely in the use of the latter intermediate compound that has recently attracted the attention of scientists around the world. An important advantage of this hard-to-synthesize and short-lived (rapidly decaying) compound is its high reactivity. To obtain the maximum yield of 1-cyanomethyl-substituted isoquinolines, optimal reaction conditions were determined and a new method for isolating its products was developed.

The scientists started with mixing reagents that allow the synthesis of dehydrobenzol in situ, and then added isoquinoline. In order to follow the reaction and see how much it has been realized, a thin-layer chromatography method (plates with alumina or silica gel applied) was used. When the complete conversion of the starting reagents occurs, the reaction is terminated. Then, to isolate the desired compound, a column chromatography method was used. It lies in the following: glass tubes are filled with the carrier (silica gel), and then the substance is introduced there and everything is washed with the solvent until get a pure substance. Finally, the scientists remove the solvent, crystallize the solid, filter the crystals and measure their melting point, and then the substance is identified by NMR spectroscopy and mass spectrometry.

The biological activity of the new substance is yet to be investigated. This is complicated and requires significant funding, therefore at the moment the primary bioscreening of the obtained compounds in done: affect of the new compounds on cells and ferments is established.

"At our department, one can find out whether the compound is an inhibitor of acetyl- or butyrylcholinoestearases. If so, it could potentially help in the fight against Alzheimer's disease," Borisova noted.

In the future, the team of researchers of the Department of Organic Chemistry, RUDN University, plans to undertake further research on reactions of nitrogen-containing heterocyclic compounds, including isoquinolines with alkynes and alkenes, in order to synthesize potentially biologically active compounds.

###

Media Contact

Valeriya V. Antonova
[email protected]

http://eng.rudn.ru/

Related Journal Article

http://dx.doi.org/10.1016/j.mencom.2017.09.026

Share12Tweet8Share2ShareShareShare2

Related Posts

Synchronous Climbing Fibers Drive Cerebellar Learning Signals

May 14, 2026
FAU’s CA-AI Awarded $2.2M U.S. Air Force Grant to Advance Next-Generation Autonomous Systems — Technology and Engineering

FAU’s CA-AI Awarded $2.2M U.S. Air Force Grant to Advance Next-Generation Autonomous Systems

May 14, 2026

Parkinson’s in Isolated Congenital Anosmia Case

May 14, 2026

Advances in Space Physiology and Wearable Tech: Adaptations, Solutions, and Future Opportunities

May 14, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    842 shares
    Share 337 Tweet 211
  • New Study Reveals Plants Can Detect the Sound of Rain

    729 shares
    Share 291 Tweet 182
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    62 shares
    Share 25 Tweet 16
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Synchronous Climbing Fibers Drive Cerebellar Learning Signals

FAU’s CA-AI Awarded $2.2M U.S. Air Force Grant to Advance Next-Generation Autonomous Systems

Parkinson’s in Isolated Congenital Anosmia Case

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.